Grassley investigating EPO marketing
Executive Summary
Senator Charles Grassley, R-Iowa, continues oversight of erythropoiesis-stimulating agents with a request for information about Johnson & Johnson's marketing of Procrit. The May 30 letter follows a similar request for a briefing and documents related to Amgen's EPO products (1"The Pink Sheet" May 28, 2007, In Brief)...
You may also be interested in...
Amgen marketing documents sought by N.Y. Attorney General
New York State Attorney General's Office subpoenas "documents related to Amgen's promotional activities, sales and marketing activities, medical education, clinical studies, pricing and contracting, license and distribution agreements and corporate communications," company discloses in a May 22 SEC filing. It is unclear whether the documents are related to a specific product, although the likely suspects are erythropoiesis-stimulating agentsAranesp (darbepoetin alfa) and Epogen (epoetin alfa). The firm also recently has come under scrutiny from Sen. Charles Grassley, R-Iowa, who is looking into Amgen's marketing practices for its EPO products, and how well it is providing drug safety information to FDA...
Boehringer Ingelheim, Gubra Enter Third Obesity Deal
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
First Phase III Data For Inovio's Immunotherapy VGX-3100 Encouraging In Cervical Dysplasia
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: